DSM-FIRMENICH AG

DSM‑Firmenich’s Q2 beats forecasts, driving a 12% share jump as the company sets a bold 2026 growth plan and highlights sustainability, cost efficiency, and strategic acquisitions as key drivers.

DSM‑Firmenich’s first‑half 2026 results show a 5 % sales rise and 20 % EBITDA margin, driven by specialty ingredients, cost cuts, and a growing plant‑based portfolio, yet regulatory and raw‑material risks loom.

DSM‑Firmenich joins the SMI Mid, boosting liquidity and investor exposure while spotlighting its niche chemistry strengths, sustainability risks, and growth opportunities.

DSM‑Firmenich AG expands European reach with Swiss dual listing, boosting investor access, index inclusion, and growth potential.

DSM‑Firmenich’s €500 M share‑repurchase boosts EPS, while its dual‑stream oat beta‑glucan research positions the company to seize clean‑label nutrition growth—yet supply and regulatory risks loom.

DSM‑Firmenich’s 2026 ex‑dividend and capital‑adjustment shift boosts value, fuels sustainability R&D, and opens M&A prospects amid growing specialty‑ingredient demand.

DSM‑Firmenich’s accelerated share‑repurchase boosts EPS, improves leverage, and follows German & Swiss rules, yet balances shareholder returns with rising ESG scrutiny.

DSM‑Firmenich’s €500 m share‑repurchase aims to boost EPS and ROE—find out how the buyback, sustainability focus, and market risks shape shareholder value.

DSM‑Firmenich’s new buy‑back, R&D focus and premium skin‑care, nutrition pipeline drive higher EPS and margin‑growth, positioning it for sustained success in a tightening ingredients market.

Mehdi Lisi’s move to Symrise signals a strategic shift in the fine‑fragrance market, blending DSM‑Firmenich’s sustainability and innovation expertise to boost competitiveness and regulatory readiness.